Cardiovascular and Neurological Outcomes in Patients Treated with Edoxaban for Atrial Fibrillation and Characteristics in Patients with Cancer.
Kai-Hung ChengHung-Pin TuKai-Chun ChengMarielle Scherrer-CrosbieTing-Yuan HsuPublished in: medRxiv : the preprint server for health sciences (2023)
These findings have important clinical implications. Edoxaban appears to be a superior anticoagulant choice for AF patients, as it lowers the risk of CHF and AD. This highlights the potential of edoxaban to improve patient outcomes and underscores its relevance for managing AF cases.
Keyphrases
- atrial fibrillation
- venous thromboembolism
- direct oral anticoagulants
- left atrial
- end stage renal disease
- oral anticoagulants
- catheter ablation
- left atrial appendage
- ejection fraction
- newly diagnosed
- heart failure
- percutaneous coronary intervention
- coronary artery disease
- type diabetes
- metabolic syndrome
- patient reported outcomes
- decision making
- blood brain barrier
- subarachnoid hemorrhage
- risk assessment
- insulin resistance
- left ventricular